PL2852408T3 - Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu - Google Patents

Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu

Info

Publication number: PL2852408T3
Authority: PL; Poland
Prior art keywords: cancer; treatment; combination therapy; antibodies against; therapy involving
Prior art date: 2012-05-23

Application number

PL13724523T

Other languages

English (en)

Inventor

Ugur Sahin

Özlem Türeci

Rita Mitnacht-Kraus

Stefan Denis Jacobs

Magdalena Jadwiga Utsch

Cornelia Adriana Maria Heinz

Christiane Regina Stadler

Original Assignee

Ganymed Pharmaceuticals Gmbh

Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-23

Filing date

2013-05-21

Publication date

2017-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2852408(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-23 Priority claimed from PCT/EP2012/002210 external-priority patent/WO2013174403A1/en

2013-05-21 Application filed by Ganymed Pharmaceuticals Gmbh, Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical Ganymed Pharmaceuticals Gmbh

2017-12-29 Publication of PL2852408T3 publication Critical patent/PL2852408T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

PL13724523T 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu PL2852408T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/EP2012/002210 WO2013174403A1 (en)	2012-05-23	2012-05-23	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
PCT/EP2013/001504 WO2013174510A1 (en)	2012-05-23	2013-05-21	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP13724523.9A EP2852408B1 (en)	2012-05-23	2013-05-21	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number	Publication Date
PL2852408T3 true PL2852408T3 (pl)	2017-12-29

Family

ID=52544200

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13724523T PL2852408T3 (pl)	2012-05-23	2013-05-21	Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
PL17171169T PL3254695T3 (pl)	2012-05-23	2013-05-21	Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL17171169T PL3254695T3 (pl)	2012-05-23	2013-05-21	Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu

Country Status (9)

Country	Link
EP (6)	EP3791896B1 (pl)
CY (3)	CY1119549T1 (pl)
DK (1)	DK3254695T3 (pl)
HR (1)	HRP20171218T1 (pl)
ME (1)	ME02932B (pl)
PL (2)	PL2852408T3 (pl)
RS (1)	RS56187B1 (pl)
SI (1)	SI2852408T1 (pl)
SM (1)	SMT201700387T1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3791896B1 (en)	2012-05-23	2024-01-10	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11202007055QA (en) *	2018-03-08	2020-09-29	Phanes Therapeutics Inc	Anti-claudin 18.2 antibodies and uses thereof
EP3858384A4 (en)	2018-09-30	2022-07-06	CRAGE medical Co., Limited	COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
CN109762067B (zh) *	2019-01-17	2020-02-28	北京天广实生物技术股份有限公司	结合人Claudin 18.2的抗体及其用途
CN111978402B (zh) *	2019-05-24	2022-06-28	三优生物医药(上海)有限公司	新型cldn18.2结合分子
CA3141504A1 (en)	2019-05-24	2020-12-03	Sanyou Biopharmaceuticals Co., Ltd.	Novel cldn18.2 binding molecule
CN111704669B (zh) *	2020-07-13	2022-05-13	北京凯因科技股份有限公司	一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN112480248B (zh) *	2020-11-24	2023-05-05	三优生物医药(上海)有限公司	与cld18a2特异性结合的分子
CN115073596B (zh) *	2021-03-10	2025-06-27	上海莱馥医疗科技有限公司	一种人源化Claudin18.2抗体及其应用
CN114685670B (zh) *	2020-12-31	2025-06-27	上海莱馥医疗科技有限公司	Cldn18.2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
KR20110017020A (ko)	2002-10-17	2011-02-18	젠맵 에이/에스	Ｃｄ20에 대한 인간 모노클로날 항체
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
US8445219B2 (en) *	2008-07-25	2013-05-21	Merck Patent Gmbh	Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2011090005A1 (ja) *	2010-01-19	2011-07-28	協和発酵キリン株式会社	大腸癌の治療用医薬および治療方法
WO2013174403A1 (en)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3791896B1 (en)	2012-05-23	2024-01-10	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

2013
- 2013-05-21 EP EP20194625.8A patent/EP3791896B1/en not_active Revoked
- 2013-05-21 EP EP24150410.9A patent/EP4364756A3/en not_active Withdrawn
- 2013-05-21 EP EP17171169.0A patent/EP3254695B1/en not_active Revoked
- 2013-05-21 RS RS20170793A patent/RS56187B1/sr unknown
- 2013-05-21 PL PL13724523T patent/PL2852408T3/pl unknown
- 2013-05-21 HR HRP20171218TT patent/HRP20171218T1/hr unknown
- 2013-05-21 DK DK17171169.0T patent/DK3254695T3/da active
- 2013-05-21 PL PL17171169T patent/PL3254695T3/pl unknown
- 2013-05-21 EP EP13724523.9A patent/EP2852408B1/en active Active
- 2013-05-21 EP EP25164108.0A patent/EP4556071A3/en active Pending
- 2013-05-21 SI SI201330741T patent/SI2852408T1/sl unknown
- 2013-05-21 ME MEP-2017-187A patent/ME02932B/me unknown
- 2013-05-21 EP EP25163274.1A patent/EP4556070A3/en active Pending
- 2013-05-21 SM SM20170387T patent/SMT201700387T1/it unknown
2017
- 2017-08-17 CY CY20171100876T patent/CY1119549T1/el unknown
2020
- 2020-11-30 CY CY20201101136T patent/CY1123593T1/el unknown
2024
- 2024-02-02 CY CY20241100095T patent/CY1126654T1/el unknown

Also Published As

Publication number	Publication date
EP4556071A3 (en)	2025-08-27
EP2852408A1 (en)	2015-04-01
EP3791896A1 (en)	2021-03-17
CY1119549T1 (el)	2018-03-07
EP3254695A1 (en)	2017-12-13
EP2852408B1 (en)	2017-05-17
EP3791896B1 (en)	2024-01-10
DK3254695T3 (da)	2020-11-30
EP4364756A2 (en)	2024-05-08
EP4556070A3 (en)	2025-08-27
EP4364756A3 (en)	2024-07-31
EP3254695B1 (en)	2020-09-09
EP4556070A2 (en)	2025-05-21
CY1123593T1 (el)	2022-03-24
HRP20171218T1 (hr)	2017-10-20
RS56187B1 (sr)	2017-11-30
EP4556071A2 (en)	2025-05-21
SMT201700387T1 (it)	2017-09-07
ME02932B (me)	2018-04-20
CY1126654T1 (el)	2026-02-25
SI2852408T1 (sl)	2017-10-30
PL3254695T3 (pl)	2021-04-06

Publication	Publication Date	Title
IL279330A (en)	2021-01-31	Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en)	2020-09-30	Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL239981A0 (en)	2015-08-31	Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
IL240060A0 (en)	2015-09-24	Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
PT2804599T (pt)	2019-01-28	Terapêutica de associação para o tratamento de cancro
PL3254695T3 (pl)	2021-04-06	Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
IL263781A (en)	2019-01-31	Combined treatment of ovarian cancer
IL240599A0 (en)	2015-09-24	Combined treatment to treat the formation of acne
SMT202200458T1 (it)	2023-01-13	Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
SI2976360T1 (sl)	2020-04-30	Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
IL233495A0 (en)	2014-08-31	Combination for cancer treatment